Most Active Healthcare Stocks Today (NASDAQ:HGSI, RPRX, GERN )

Subscribe to FREE Alerts by visiting: http://www.PennyStockPickReport.com if are planning to make money in the penny stock market.

Human Genome Sciences (NASDAQ:HGSI)  is amongst the top volume gainers in the early morning trade and jumped up 4.76% to $20.90 on a massive volume of 3.27 million shares after it announced that it has earned a $75 million payment from Novartis, related to successful completion of the Phase 3 development program and the decision to submit applications seeking regulatory approval to market ZALBIN (albinterferon alfa-2b) for the treatment of chronic hepatitis C. Human Genome Sciences and Novartis have completed pre-submission meetings with the FDA and European regulatory agencies, and plan to submit marketing authorization applications for albinterferon alfa-2b, an investigational treatment for chronic hepatitis C, in the fourth quarter of 2009.   The stock has a 52-week range of $0.45-$22.78. Human Genome Sciences (HGS) is a commercially focused biopharmaceutical company. The Company has three products in late-stage clinical development: Albuferon for chronic hepatitis C, LymphoStat-B for systemic lupus erythematosus and ABthraxtm for inhalation anthrax.

Repros Therapeutics Inc. (NASDAQ:RPRX)     soared 7.81% to $1.38 on huge volume of 974k shares on no news. The stock has a 52-week range of $0.65-$13.94. Repros Therapeutics Inc. (RPRX) is a development-stage biopharmaceutical company focused on the development of oral small molecule drugs for unmet medical needs. The Company's principal drug, Proellex, is a selective blocker of the progesterone receptor and is being developed for the treatment of uterine fibroids, anemia associated with excessive menstrual bleeding relating to uterine fibroids, or anemia associated with uterine fibroids and endometriosis.

Geron Corporation (NASDAQ:GERN) jumped 5.85% to $6.88 with a huge volume of 414k shares on no news. The stock has a 52-week range of $2.48-$9.24. Geron Corporation (Geron), is developing therapeutic products for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure and diabetes. The Company is advancing telomerase targeted therapies, including an anti-cancer drug and a cancer vaccine, through multiple clinical trials. Geron also develops human embryonic stem cell (hESC)-based therapeutics.

ABOUT PennyStockPickReport

Penny Stock Pick Report alerts investors on Top Stocks that would help investors to generate higher than average returns. These include various types of stocks with huge volume, penny stocks that are moving to the upside quickly, penny stocks with buy signals and companies with news. Our regular Stock Alerts helps investors to achieve incredible results in a short amount of time and our members have made remarkable profits of over 100%.